Hannah Joseph Hospital Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Hannah Joseph Hospital Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹70
Per ShareLot Size
2000 Shares
Minimum Investment
₹1,40,000
Issue Size
₹42 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Hannah Joseph Hospital Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
93.57%
Promoter Holding (Post-Issue)
68.83%
Issue Type
Book Building - SME
ISIN
INE0JVH01012
About the Company
With an objective to provide comprehensive range of neurosurgery and neurology services, Mosesjoseph Arunkumar established a hospital in the name of `Hannah Joseph Hospital' as a sole proprietorship in Madurai town of Tamil Nadu, in 2008. On September 9, 2008, the hospital became a member of Nursing Homes and Hospital Board, Indian Medical Association Tamil Nadu State.
Industry Overview
Healthcare has become one of India's largest sectors, both in terms of revenue and employment. Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance and medical equipment. The Indian healthcare sector is growing at a brisk pace due to its strengthening coverage, services, and increasing expenditure by public as well as private players. India's healthcare delivery system is categorised into two major components public and private. The government, i.e., the public healthcare system, comprises limited secondary and tertiary care institutions in key cities and focuses on providing basic healthcare facilities in the form of Primary Healthcare Centers (PHCs) in rural areas. The private sector provides the majority of secondary, tertiary, and quaternary care institutions with a major concentration in metros, tier-I, and tier-II cities.
Company History
The Company was incorporated as "Hannah Joseph Hospital Private Limited" at Tamil Nadu as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 24, 2011, issued by the Registrar of Companies ("ROC"), Tamil Nadu, Chennai, Andaman and Nicobar Islands Subsequently, the Company was converted to a public limited company and the name of the Company changed to `Hannah Joseph Hospital Limited' and a fresh certificate of incorporation dated July 29, 2022 was issued by the RoC, Chennai. The CIN of the Company is U74999TN2011PLC082860.
Products & Services
- The Company started with an objective to provide comprehensive range of neurosurgery and neurology services.
Growth Strategy
- Commitment to Excellence in Healthcare Services.
- Skilled Medical Team and Retention Strategy.
- Strategic Location and Expansion Focus.
- Infrastructure and Machinery used in the Hospital.
- Enhancing Operational Excellence.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public issue of up to 60,00,000 equity shares of face value of Rs. 10/- each ("Equity Shares") of Hannah Joseph Hospital Limited ("Company" / "Issuer") for cash at a price of Rs.70 per equity share (including a share premium of Rs.60 per equity share) ("Issue Price") aggregating up to Rs.42 crores ("Issue"), of which 3,00,000 equity shares of face value of Rs. 10/- each for cash at a price of Rs.70 per equity share including a share premium of Rs.60 per equity share aggregating to Rs. 2.1 crores will be reserved for subscription by market maker to the issue (the "Market Maker Reservation Portion"). The issue less the market maker reservation portion i.e. net issue of 57,00,000 equity shares of face value of Rs. 10/- each at a price of Rs.70 per equity share including a share premium of Rs.60 per equity share aggregating to Rs.39.9 crores is herein after referred to as the "Net Issue". The issue and the net issue will constitute 26.43% and 25.11%, respectively, of the post issue paid up equity share capital of the company. Price Band: Rs. 70/- for equity share of face value of Rs. 10 each. The floor is 7.00 times of the face value of the equity shares. Bids can be made for a minimum of 4000 equity shares and in multiples of 2000 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Founder led company supported by a highly experienced and professional management team.
- Company is reputed for providing quality health care and wellness.
- High consistency and success rates in handling complicated surgeries.
- Growth opportunities in existing facilities and diversification into new services.
- Ability to attract and retain high quality doctors, consultants and medical support staff.
- We intend to utilize a portion of the Net Proceeds for setting up the Proposed Radiation Oncology Centre adjacent to the current hospital campus. We are yet to place orders for medical equipments and apply for requisite government approvals for the Proposed Radiation Oncology Centre. If we are unable to commission our Proposed Radiation Oncology Centre without time and cost overruns or unable to adhere to the schedule of implementation it may adversely affect our business, results of operations and financial conditions.
- We are required to obtain statutory and regulatory approvals, licenses or permits for our proposed radiation oncology centre. If we fail to obtain, maintain or renew our statutory and regulatory approvals or permits, our business, results of operations, financial condition, and cash flows could be adversely affected.
- There are outstanding legal proceedings involving our Company. Any adverse decisions could impact our net worth, profitability, cashflows and divert management time and attention and have an adverse effect on our business, prospects, results of operations and financial condition.
- Our Company did not open a separate bank account for private placements made in the past, utilized the proceeds from the issuance prior filing of Form PAS- 3, and issued private placement offer cum application letter before filing the Form MGT-14 with registrar and determined the relevant date within 30 days prior to the date of general meeting in violation of Section 42 of the Companies Act, 2013 and the rules made thereunder, which may have a material adverse effect on our business.
- There may have been certain instances of irregularities, discrepancies and non-compliances with respect to certain corporate actions taken by our Company in the past. Consequently, we may be subject to regulatory actions and penalties.